Illumina, Inc. (NASDAQ:ILMN) – Stock analysts at First Analysis boosted their Q4 2017 earnings per share (EPS) estimates for Illumina in a research note issued to investors on Wednesday, Zacks Investment Research reports. First Analysis analyst T. Marshbanks now anticipates that the life sciences company will post earnings per share of $1.18 for the quarter, up from their prior estimate of $1.09. First Analysis has a “Equal Weight” rating and a $176.00 price target on the stock.
Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Tuesday, October 24th. The life sciences company reported $1.11 EPS for the quarter, topping the Zacks’ consensus estimate of $0.99 by $0.12. Illumina had a return on equity of 19.42% and a net margin of 30.34%. The business had revenue of $714.00 million for the quarter, compared to analyst estimates of $692.77 million. During the same period last year, the company posted $0.97 earnings per share. Illumina’s quarterly revenue was up 17.6% compared to the same quarter last year. TRADEMARK VIOLATION NOTICE: This story was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this story on another publication, it was copied illegally and republished in violation of U.S. and international copyright laws. The legal version of this story can be viewed at https://www.dispatchtribunal.com/2017/11/12/q4-2017-eps-estimates-for-illumina-inc-raised-by-analyst-ilmn.html.
A number of other research firms also recently issued reports on ILMN. Deutsche Bank AG set a $175.00 target price on Illumina and gave the stock a “hold” rating in a research report on Friday, July 28th. Citigroup Inc. raised their target price on Illumina from $180.00 to $220.00 and gave the stock a “neutral” rating in a research report on Wednesday, October 25th. Canaccord Genuity upgraded Illumina from a “hold” rating to a “buy” rating and lifted their price target for the company from $170.00 to $215.00 in a research report on Monday, August 7th. Robert W. Baird upgraded Illumina from a “neutral” rating to an “outperform” rating and lifted their price target for the company from $184.00 to $228.00 in a research report on Wednesday, October 25th. Finally, Zacks Investment Research upgraded Illumina from a “hold” rating to a “buy” rating and set a $229.00 price target for the company in a research report on Friday, October 27th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and thirteen have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $200.88.
Shares of Illumina (NASDAQ ILMN) opened at $208.94 on Friday. The company has a debt-to-equity ratio of 0.41, a current ratio of 4.22 and a quick ratio of 3.73. Illumina has a 52-week low of $119.37 and a 52-week high of $214.50. The stock has a market capitalization of $30,603.06, a price-to-earnings ratio of 61.29, a price-to-earnings-growth ratio of 3.46 and a beta of 0.74.
Hedge funds have recently added to or reduced their stakes in the stock. Paradigm Asset Management Co. LLC lifted its position in Illumina by 5.6% in the 2nd quarter. Paradigm Asset Management Co. LLC now owns 950 shares of the life sciences company’s stock valued at $165,000 after acquiring an additional 50 shares in the last quarter. Patriot Financial Group Insurance Agency LLC lifted its holdings in shares of Illumina by 1.4% during the 2nd quarter. Patriot Financial Group Insurance Agency LLC now owns 3,126 shares of the life sciences company’s stock valued at $528,000 after buying an additional 43 shares during the period. Cambridge Investment Research Advisors Inc. lifted its holdings in shares of Illumina by 298.7% during the 2nd quarter. Cambridge Investment Research Advisors Inc. now owns 10,447 shares of the life sciences company’s stock valued at $1,813,000 after buying an additional 7,827 shares during the period. Eagle Asset Management Inc. bought a new position in shares of Illumina during the 2nd quarter valued at $27,175,000. Finally, Stephens Investment Management Group LLC lifted its holdings in shares of Illumina by 0.5% during the 2nd quarter. Stephens Investment Management Group LLC now owns 168,706 shares of the life sciences company’s stock valued at $29,274,000 after buying an additional 803 shares during the period. 93.07% of the stock is currently owned by institutional investors and hedge funds.
In related news, Director Jay T. Flatley sold 20,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 15th. The stock was sold at an average price of $194.73, for a total value of $3,894,600.00. Following the sale, the director now owns 539,176 shares in the company, valued at approximately $104,993,742.48. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Charles Dadswell sold 1,609 shares of the company’s stock in a transaction that occurred on Friday, November 3rd. The stock was sold at an average price of $207.88, for a total value of $334,478.92. Following the completion of the sale, the senior vice president now owns 7,217 shares in the company, valued at approximately $1,500,269.96. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 187,964 shares of company stock worth $38,454,069. 1.60% of the stock is owned by company insiders.
Illumina Company Profile
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Get a free copy of the Zacks research report on Illumina (ILMN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.